Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 22, 2012

GE Healthcare, Karolinska University Ally to Enable Routine Application of Cell Therapies

  • GE Healthcare Life Sciences and Karolinska University Hospital established a collaboration to develop the technologies and workflows that will be needed to apply cell therapies routinely in a clinical setting. The goal is to address the need for reproducible technologies in areas such as cell growth, handling, processing, and analysis as well as protocols and workflows for manufacturing and quality control.

    The partnership will combine GE’s cell biology and biomanufacturing capabilities with Karolinska’s clinical expertise in cell therapy. The ultimate aim is to solve the problems that currently prevent cell therapies from becoming routinely applicable, explains Johan Permert, Ph.D., director for development and innovation at Karolinska University Hospital.

    “This collaboration is the first initiative to develop enhanced interaction between Karolinska University Hospital and industry," Dr. Permert adds. "By involving not only researchers and industry partners but also the public healthcare system, we are aiming to develop methods and tools that accelerate the implementation of cell therapies into standard treatment.” 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »